PHR1892

ボリコナゾール

Pharmaceutical Secondary Standard: Certified Reference Material

• 別名: ボリコナゾール, 2R,3S-2-(2,4-ジフルオロフェニル)-3-(5-フルオロピリミジン-4-イル)-1-(1H-1,2,4-トリアゾール-1-イル)ブタン-2-オール, UK-109496
• 実験式（ヒル表記法）: C₁₆H₁₄F₃N₅O
• CAS番号: 137234-62-9
• 分子量: 349.31
• MDL番号: MFCD00905717
• UNSPSCコード: 41116107
• NACRES: NA.24

特性

• グレード: certified reference material; pharmaceutical secondary standard
• 品質水準: 300
• 認証: traceable to Ph. Eur. Y0001395; traceable to USP 1718008
• APIファミリー: voriconazole
• CofA: current certificate can be downloaded
• 包装: pkg of 1 g
• アプリケーション: pharmaceutical
• フォーマット: neat
• 保管温度: 2-8°C
• SMILES記法: C[C@@H](c1ncncc1F)[C@](O)(Cn2cncn2)c3ccc(F)cc3F
• InChI: 1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1
• InChI Key: BCEHBSKCWLPMDN-MGPLVRAMSA-N

詳細

詳細

Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards

Voriconazole is a synthetically prepared, broad-spectrum triazole derivative of fluconazole, which shows in vitro activity against many yeasts and a broad-spectrum of mold and dermatophyte isolates. Its mode of action involves the inhibition of cytochrome P450 (CYP)-dependent enzyme, 14-α-sterol demethylase, and hence it is involved in disrupting the cell membrane and terminate the fungal growth.

アプリケーション

These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Voriconazole may be used as a pharmaceutical reference standard for the quantification of the analyte in pharmaceutical formulations using high-performance liquid chromatography technique.

生物化学的／生理学的作用

ボリコナゾールは、抗真菌薬として重度の真菌感染症の治療に使用されています。

ボリコナゾールは、重篤な真菌感染の治療で使用される抗真菌薬です。ボリコナゾールは、CYP450依存性の14-αステロールデメチラーゼを阻害することでエルゴステロール合成を阻害し、真菌細胞膜におけるエルゴステロールの欠乏を引き起こします。

アナリシスノート

このような2次標準は、入手可能な場合にはUSP、EP、BPの1次標準にマルチトレーサビリティを提供します。

その他情報

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

脚注

To see an example of a Certificate of Analysis for this material enter LRAC2092 in the Documents slot below. This is an example certificate only and may not be the lot that you receive.

安全性情報

• ピクトグラム: GHS06,GHS08
• シグナルワード: Danger
• 危険有害性情報: H301,H341,H351,H361,H371,H372,H373,H412
• 注意書き: P202 - P260 - P264 - P270 - P273 - P301 + P310
• 危険有害性の分類: Acute Tox. 3 Oral - Aquatic Chronic 3 - Carc. 2 - Muta. 2 - Repr. 2 - STOT RE 1 - STOT RE 2 Oral - STOT SE 2 Oral
• ターゲットの組織: Eyes, Liver,Kidney
• 保管分類コード: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable